Theravance Biopharma, Inc. (TBPH) Form 8-K — Sep 23, 2026
$TBPHForm 8-KItems 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01Filed Sep 23, 2026, 4:17 PM ET0001104659-26-109979Original filing
Theravance Biopharma completed its merger with Zymeworks Inc. on September 23, 2026, with the company surviving as a wholly owned subsidiary of Zymeworks. Each TBPH ordinary share was converted into the right to receive $17.00 in cash plus one contingent value right. The CVRs are non-tradeable and entitle holders to a pro rata share of 80% of net proceeds from any license or monetization of ampreloxetine within ten years, $50 million in aggregate (i.e., $0.93 per CVR) upon first commercial sale in major markets, and 10% of net sales thereafter.
Key figures
- Per Share Cash Consideration
- $17.00
- Cvr term years
- 10
- Cvr royalty rate
- 10% of Net Sales
- Cvr license proceeds share
- 80% of Net License Proceeds
- Consultation advisor expense cap
- $400,000
- First commercial sale milestone payment
- $50 million aggregate ($0.93 per CVR)
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.